PT - JOURNAL ARTICLE AU - Marina Avramescu AU - Pierre Isnard AU - Sarah Temmam AU - Agnès Chevalier AU - Paul Bastard AU - Mikael Attia AU - Romain Berthaud AU - Marc Fila AU - Claire Dossier AU - Julien Hogan AU - Tim Ulinski AU - Damia Leguevaques AU - Férielle Louillet AU - Edouard Martinez Casado AU - Jean-Michel Halimi AU - Sylvie Cloarec AU - Ariane Zaloszyc AU - Camille Faudeux AU - Caroline Rousset-Rouvière AU - Stéphanie Clavé AU - Jérôme Harambat AU - Edouard Rollot AU - Thomas Simon AU - Megan Nallet-Amate AU - Bruno Ranchin AU - Justine Bacchetta AU - Florence Porcheret AU - Josselin Bernard AU - Amélie Ryckewaert AU - Anne Jamet AU - Jacques Fourgeaud AU - Nicolas Da Rocha AU - Philippe Pérot AU - Nicolas Kuperwasser AU - Naïm Bouazza AU - Marion Rabant AU - Jean-Paul Duong Van Huyen AU - Matthieu P Robert AU - Julien Zuber AU - Jean-Laurent Casanova AU - Marc Eloit AU - Isabelle Sermet-Gaudelus AU - Olivia Boyer TI - Acute tubulointerstitial nephritis with or without uveitis: a novel form of post-acute COVID-19 syndrome in children AID - 10.1101/2023.01.23.23284848 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.23.23284848 4099 - http://medrxiv.org/content/early/2023/01/26/2023.01.23.23284848.short 4100 - http://medrxiv.org/content/early/2023/01/26/2023.01.23.23284848.full AB - Background COVID-19 is a complex multisystem disease, frequently associated with kidney injury. Since the beginning of the COVID-19 pandemic, we observed a striking increase in the incidence of acute tubulointerstitial nephritis (aTIN) without or with uveitis (TINUs) among children. This prompted us to examine whether SARS-CoV-2 might be the underlying trigger.Methods We conducted a French nationwide retrospective cohort study. We included all consecutive children diagnosed with aTIN or TINUs of undetermined cause between April-2020 and March-2021. SARS-CoV-2 antibody responses were tested by a luciferase immunoprecipitation system and compared to age-matched controls. Immunohistochemistry, immunofluorescence and molecular microbiology analyses were performed on kidney biopsies.Results Forty-eight children were included with a median age at diagnosis of 14.7 years (9.4-17.6). aTIN and TINUs incidence rates increased 3-fold and 12-fold, respectively, compared to pre-pandemic years. All patients had impaired kidney function with a median eGFR of 31.9 ml/min/1.73m² at diagnosis. Kidney biopsies showed lesions of acute tubulointerstitial nephritis and 25% of patients had fibrosis. No patient had concomitant acute COVID-19. All 16 children tested had high anti-N IgG titers and one had anti-S IgGs. Next-generation sequencing failed to detect any infectious agents in kidney biopsies. However, SARS-CoV-2 RNA was detected by PCR in two kidney samples supporting a potential direct link between SARS-CoV-2 and aTIN/TINUs.Conclusions We describe a novel form of post-acute COVID-19 syndrome in children, unique in its exclusive kidney and eye involvement, and its distinctive anti-SARS-CoV-2 N+/S-serological profile. Our results support a causal association linking SARS-CoV-2 infection to this newly-reported burst of renal/eye inflammation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics board approval was granted by the local Ethics Committee of the Assistance Publique Hopitaux de Paris (Decision number: N 2022 0503154702). Informed consent was obtained from all parents or legal guardians; patients were informed about the purpose of the study and gave their assent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript